Prevalence and Clinical Correlates of Bronchoreversibility in Severe Emphysema by Han, MeiLan K. et al.
Prevalence and clinical correlates of
bronchoreversibility in severe emphysema
M.K. Han*, R. Wise#, J. Mumford", F. Sciurba+, G.J. Criner1, J.L. Curtis*, S. Murraye,
A. Sternberg#, G. Weinman**, E. Kazerooni##, A.P. Fishman"", B. Make++,
E.A. Hoffman11, Z. Mosenifaree and F.J. Martinez* for the NETT Research Group***
ABSTRACT: Chronic obstructive pulmonary disease (COPD) exhibits airflow obstruction that is
not fully reversible. The importance of bronchoreversibility remains controversial.
We hypothesised that an emphysematous phenotype of COPD would be associated with
decreased bronchoreversibility.
544 patients randomised to the medical arm of the National Emphysema Treatment Trial formed
the study group. Participants underwent multiple measurements of bronchoreversibility on a
mean of four sessions over 1.91 yrs. They were also characterised by measures of symptoms,
quality of life and quantitative measures of emphysema by computed tomography.
Mean baseline forced expiratory volume in 1 s (FEV1) in this patient population is 24%
predicted. 22.2% of patients demonstrated bronchoreversibility on one or more occasions using
American Thoracic Society/European Respiratory Society criteria. Few patients (0.37%) had
bronchoreversibility on all completed tests. Patients who demonstrated bronchoreversibility were
more likely to be male, and have better lung function and less emphysema. 64% of patients
demonstrated large (o400 mL) changes in forced vital capacity (FVC).
In a severe emphysema population, bronchoreversibility as defined by change in FEV1 is
infrequent, varies over time, and is more common in males and those with less severe
emphysema. Improvements in FVC, however, were demonstrated in the majority of patients.
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W
ith the recent demonstration that lung
volume reduction therapy benefits
selected patients with severe emphy-
sema [1], accurate diagnosis and staging of
patients with chronic obstructive pulmonary
disease (COPD) assumes a new importance. In
such clinical evaluations, however, it is uncertain
how much weight should be accorded to
physiological data versus imaging modalities. In
particular, the role of bronchoreversibility in
excluding asthma and defining varying clinical
phenotypes in COPD patients remains contro-
versial [2]. COPD has been characterised as a
disorder with airflow obstruction that is not
fully reversible [3, 4], but bronchoreversibility
has been confirmed in a substantial proportion
of patients clinically diagnosed with nonasth-
matic COPD [5–7]. However, some studies have
shown acute bronchodilator responses in small
proportions of patients, similar to a normal
population [8] but in contrast to the findings of
others [9]. Careful prospective analyses are
needed to define the relationships between
diagnostic and staging modalities, and to avoid
arbitrary patient classification. Given the limited
data on the presence of bronchoreversibility in
patients with emphysema [10–12], we examined
bronchoreversibility in patients with computed
tomography (CT)-defined emphysema rando-
mised to the medical arm of the National
Emphysema Treatment Trial (NETT). We
hypothesised that patients with emphysema
would rarely demonstrate bronchoreversibility
and that greater emphysema volume, as quanti-
fied by CT, would be associated with decreased
bronchoreversibility.
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METHODS
Patient selection
The study group of 544 patients includes patients randomised
to medical therapy at 17 clinics as part of the NETT and in
whom quantitative measurement of emphysema volume and
distribution was available (see below). The design and
methods of the trial have been previously detailed [13].
Major enrolment criteria include bilateral emphysema evalu-
ated by chest CT and determined to be suitable for lung
volume reduction, forced expiratory volume in 1 s (FEV1)
f45% predicted, total lung capacity (TLC) o100% pred,
residual volume o150% pred and arterial carbon dioxide
tension f60 mmHg (55 mmHg in Denver, CO, USA). All
patients had to be validated nonsmokers for o4 months prior
to screening and be free of any important comorbidity. All
patients provided written informed consent, and the study was
approved by the institutional review board at each clinic.
Clinical assessment
Demographic data and medical history were collected by
patient interview using standardised instruments.
Physiological testing
Patients underwent spirometry before and after two inhala-
tions of albuterol (total of 116 mg) via metered-dose inhaler,
while plethysmographic lung volumes and diffusing capacity
of the lung for carbon monoxide (DL,CO) were measured
15 min after albuterol administration. Per protocol, broncho-
dilators were held for 4 h prior to pulmonary function testing.
All spirometric manoeuvres met or exceeded American
Thoracic Society (ATS)/European Respiratory Society (ERS)
criteria for acceptability; the forced vital capacity (FVC)
manoeuvres lasted or exceeded 6 s [14]. Arterial blood gases
were also measured but at the discretion of the clinic staff with
respect to bronchodilator administration. Spirometry, before
and after albuterol administration, was repeated after pul-
monary rehabilitation and then at 6, 12, 24, 36, 48 and
60 months after randomisation. Inspiratory resistance mea-
surements were available in 91 subjects as part of a substudy
performed at four centres. Data on expiratory time was not
recorded as part of the original dataset but was retrospectively
collected on 100 randomly selected subjects as part of
additional analyses for this manuscript.
Diagnostic imaging studies
Emphysema severity and distribution was determined from
chest CT scans obtained at full inspiration. After segmenting
and dividing the lung according to previously described
protocols [15], images were analysed using custom-built
software, the Pulmonary Analysis Software Suite. The density
histogram was plotted, with values less than -950 HU
corresponding to severe emphysema and regions with values
of -910 HU and -850 HU roughly equating to moderate and
mild emphysema, respectively. The alpha value (inverse slope)
was determined from the log–log relationship of hole size
versus number of holes [16]. Lungs with greater proportions of
small lesions have a steep negative slope and a large alpha.
Statistical analyses
To define a positive response to albuterol, we performed
analyses using criteria for bronchoreversibility based on ATS/
ERS joint guidelines, defined as an increase in FEV1 of
o200 mL and o12% absolute value [17]. In addition, we
examined the proportion of patients that experienced an
absolute increase in FEV1 o400 mL [18] and those that
experienced both a o400 mL increase in FVC and a o12%
rise in absolute FVC. Logistic regression analyses were used to
evaluate the impact of demographic features, baseline pul-
monary physiology, and quantity and distribution of emphy-
sema on the presence of a positive response to albuterol.
Unpaired t-tests were used to compare continuous measures
between the groups who met the different criteria to those who
never met the criteria. Chi-squared tests were used to compare
bivariate measures across groups unless cell counts were less
than five, in which case a Fisher’s exact test was used. To
assess whether a subject’s ATS/ERS criteria at one time point
agreed with their criteria at the next time point, kappa statistics
were calculated. Finally, as this is an exploratory analysis, no
adjustment for multiple comparisons was made. As such, it is
possible by chance alone that one in 20 comparisons may be
spuriously statistically significant.
RESULTS
544 patients randomised to medical therapy who had
quantification of emphysema volume and distribution at
baseline and pre- and post-bronchodilator FEV1 measured at
the pre-rehabilitation visit formed the study group. These
patients underwent a mean¡SD of 4.16¡1.58 spirometric
bronchoreversibility studies over the course of their participa-
tion in NETT (1.85¡1.30 yrs from the first bronchoreversibility
study to the last). Table 1 provides descriptive characteristics
of the study group at the pre-rehabilitation evaluation (more
extensive characterisation is available in online depository
table E1). In general, the cohort was characterised by severe
airflow obstruction and moderately severe emphysema.
Table 2 enumerates the proportion of patients at each time
point who met the ATS/ERS criteria for bronchoreversibility
TABLE 1 Pre-rehabilitation characteristics for 544 patients
with severe emphysema
Males/females n 345/199
Smoking history pack-yrs 66.1¡31.8
Age yrs 66.4¡6.0
BMI kg?m-2 24.9¡3.7
Pre-bronchodilator FEV1 % pred 24.0¡6.7
Pre-bronchodilator FVC % pred 58.1¡15.2
TLC % pred 129.0¡13.8
RV % pred 224.5¡47.1
DL,CO % pred 28.6¡9.9
Post-bronchodilator FEV1 change mL 94.6¡84.5
FEV1/FVC ratio % 31.4¡6.2
Whole lung emphysema % (-950 HU) 15.9¡10.5
Data are presented as mean¡SD, unless otherwise stated. BMI: body mass
index; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced
vital capacity; TLC: total lung capacity; RV: residual volume; DL,CO: diffusing
capacity of the lung for carbon monoxide. See table E1 in online depository for
more detailed baseline patient characteristic information.
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and the mean FEV1 at each time point. 542 underwent repeat
bronchoreversibility testing after pulmonary rehabilitation, 393
at 6 months, 328 at 12 months, 255 at 24 months, 137 at
36 months, 31 at 48 months and 20 at 60 months after
randomisation. Figure 1 illustrates the number of patients that
met ATS/ERS bronchoreversibility criteria during the first
2 yrs of follow-up. It is evident that a similar proportion of
patients met these criteria at each time point of follow-up after
randomisation (approximately f10%; fig. 1). Importantly, the
baseline pre-bronchodilator FEV1 was similar at each time
point. Kappa statistics were used to check if a patient’s ATS/
ERS criteria at one time point agreed with their criteria at the
next time point, with a high kappa (closer to 1) indicating good
agreement between time points. In all but one case, the
absolute value of the kappa statistic was ,0.4, indicating
agreement between ATS/ERS criteria from one time point to
another was most likely due to chance. In one case, a kappa of
1 was achieved (between the 36 and 48 month visits), but there
was a small sample size for this group (n526).
Similar results are enumerated in table 3 utilising varying
definitions for bronchoreversibility. For example, 121 out of
544 (22.2%) patients met the ATS/ERS bronchoreversibility
criteria at least once during multiple tests. Importantly, only two
out of 544 (0.4%) patients met this criterion during every testing
period. Using a larger absolute change in FEV1 (o400 mL
increase) identified a smaller proportion of patients that
exhibited such a level of bronchoreversibility at least once (10
out of 544; 1.8%). A 400 mL and 12% increase in FVC was seen in
a larger proportion of patients at least once (348 out of 544; 64%);
45 patients met this criterion during each testing period.
We next examined differences between varying clinical,
physiological and imaging characteristics between those
patients that met the various bronchoreversibility criteria at
least once versus those that did not (tables 4 and 5; more
detailed information available in online depository tables E4
and E5). Interestingly, proportionately fewer females (10.6%)
met the ATS/ERS reversibility criteria compared to males
(29.0%). Similarly, patients who met reversibility criteria
generally exhibited less severe physiological impairment
evidenced by a higher FEV1, FVC, DL,CO and 6-min walk
distance and lower TLC. No consistent difference was seen in
health status, symptoms or emphysema percentage.
Table 6 provides multivariate models examining various
factors that influenced the likelihood of meeting the differing
bronchoreversibility criteria. In general, males and patients
with higher FEV1 were more likely to exhibit bronchorevers-
ibility, while patients with lower per cent emphysema were
less likely to demonstrate bronchoreversibility on one or more
test sessions. Data on inspiratory lung resistance were avai-
lable in 91 patients. Among these, in patients who met ATS/
ERS criteria for bronchoreversibility as compared to those who
did not (21 versus 70), mean inspiratory resistance at baseline
visit was 3.9 versus 7.0 cmH2O?L
-1?s-1 (p50.0006). In patients
who met FVC bronchoreversibility criteria versus those who
did not (58 versus 33), the mean inspiratory resistance was 5.3
versus 8.1 cmH2O?L
-1?s-1 (p50.0004). Thus those who met
bronchoreversibility criteria actually had lower inspiratory
resistance than those who did not meet bronchoreversibility
criteria. We also repeated the multivariate analysis in table 6
predicting likelihood of meeting bronchoreversibility FVC
criteria including inspiratory resistance in the model. No
predictors met statistical significance with the smaller sample
size but a trend toward decreased likelihood of bronchorever-
sibility with increasing inspiratory resistance was seen (data
not shown). The mean pre-bronchodilator expiratory time was
15.2 s and the mean post-bronchodilator expiratory time was
16.1 s in 100 randomly selected subjects (pf0.0001). However,
the correlation between change in expiratory time after
bronchodilator and improvement in FVC after bronchodilator
was weak (r50.31). The coefficient of determination suggests
that 9% of the variability in change in FVC is predicted by
change in expiratory time.
DISCUSSION
In this large group of carefully characterised, prospectively
studied patients with severe emphysema, we show: 1) that
among patients selected for surgical therapy of severe
emphysema, bronchoreversibility meeting ATS/ERS criteria
exists in a small subgroup; 2) while the proportion of patients
TABLE 2 Number of patients who underwent measurement of spirometric bronchoreversibility at each time point, the number
that met or did not meet American Thoracic Society (ATS)/European Respiratory Society (ERS) criteria for
bronchoreversibility and the mean forced expiratory volume in 1 s (FEV1) at each time point
Time point Total n Did not meet
ATS/ERS BR criteria
Met ATS/ERS
BR criteria
Pre-bronchodilator
mean FEV1 L
Before rehabilitation 544 488 (89.7) 56 (10.3) 0.70¡0.22
After rehabilitation 542 503 (92.8) 39 (7.2) 0.70¡0.22
6 months after randomisation 393 355 (90.3) 38 (9.7) 0.70¡0.24
12 months after randomisation 328 300 (91.5) 28 (8.5) 0.72¡0.26
24 months after randomisation 255 235 (92.2) 20 (7.8) 0.73¡0.29
36 months after randomisation 137 130 (94.9) 7 (5.1) 0.71¡0.28
48 months after randomisation 31 29 (93.6) 2 (6.5) 0.76¡0.28
60 months after randomisation 20 20 (100.0) 0 (0.0) 0.76¡0.39
Data are presented as mean¡SD or n (%), unless otherwise stated. BR: bronchodilator response.
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meeting bronchoreversibility criteria varies by the physiologi-
cal criteria utilised to define a positive response, the majority of
patients exhibited large increase in FVC; 3) females are less
likely to exhibit bronchoreversibility; and 4) the quantity of
emphysema determined by high-resolution computed tomo-
graphy (HRCT) is a negative predictor of meeting a volume,
bronchoreversibility criterion. These data shed new light on
the physiological characteristics of COPD patients with severe
emphysema.
The finding that significant bronchoreversibility can be shown
among patients with advanced emphysema is further evidence
against the common belief that the airflow obstruction in
severe COPD is largely irreversible. Our data qualitatively
agree with the finding of bronchoreversibility in a significant
number of patients in the ISOLDE (Inhaled Steroids in
Obstructive Lung Disease) trial [5], and in several other recent
studies of COPD patients [7, 19–21]. The overall percentage of
patients meeting standard FEV1 criteria was lower than in
these reports, but similar to the findings in the Lung Health
Study, which included patients with mild to moderate airflow
obstruction regardless of presence or absence of emphysema
[8]. Our current data extend previous findings by examining
various physiological thresholds during multiple tests in
carefully characterised patients with advanced COPD and an
emphysematous phenotype. As such, we demonstrate that the
quantity of emphysema, assessed by CT, impacts broncho-
reversibility as defined by 12% change and 400 mL increase in
FVC. Several possible explanations exist for the association
between greater emphysema and lower likelihood of bronch-
oreversibility as defined by FVC criteria. The mechanical
interdependence of the airways and airspaces may be such that
bronchoreversibility is more difficult to elicit in patients with
more severe emphysema. The amount of airway muscle could
also be less in patients with more severe parenchymal
destruction. A recently published analysis of radiographic data
in the NETT suggests an inverse relationship between emphy-
sema severity and airway wall thickness [22]; thus, less airways
disease may be representative of this patient phenotype.
Although some have suggested that bronchoreversibility
testing should be used to rule out a diagnosis of asthma in
patients with suspected COPD [4], such testing appears to be
of limited diagnostic value in this setting [23]. One reason is
overlap between the definitions of asthma, an inflammatory
condition with at least partially reversible obstruction and
COPD (a condition with airflow limitation that is not fully
reversible [4]. Indeed, a subset of COPD patients has even been
shown to exhibit partial bronchoreversibility, increased
exhaled nitric oxide and sputum eosinophilia, markers gen-
erally more closely associated with a diagnosis of asthma [24].
The Global Initiative for Obstructive Lung Disease criteria for
COPD diagnosis do not require ‘‘lack’’ of reversibility, nor do
they include a strict reversibility criterion for COPD. The
words ‘‘not fully reversible’’ are included in the definition, but
in the spirometric criteria, no mandatory limit to reversibility is
required for COPD diagnosis. A second reason limiting the
utility of bronchoreversibility testing in this setting is that the
degree of bronchoreversibility in individual COPD patients is
variable from day to day. Although the mean increase in FEV1
in 985 COPD patients in the Intermittent Positive Pressure
Ventilation trial was 15%, 68% of the patients showed an
increase in FEV1 from baseline of greater than 15% at least once
during seven follow-up tests over 2.5–3 yrs [6]. Collectively,
these findings argue that the demonstration of bronchorevers-
ibility not be taken to exclude the diagnosis of COPD.
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FIGURE 1. Distribution of patients who underwent serial measurements of bronchoreversibility over 24 months of follow-up. h: does not meet bronchoreversibility
criterion; &: meets bronchoreversibility criterion.
TABLE 3 Number of patients (out of 544) meeting various spirometric bronchoreversibility criteria throughout the entire period of
evaluation
Criterion Patients meeting criterion
at least once
Patients not meeting criterion
at least once
Patients meeting specific
criterion at all visits
ATS/ERS 121 (22.2) 423 (77.8) 2
FEV1 o400 mL 10 (1.8) 534 (98.2) 0
FVC o400 mL and 12% increase 348 (64.0) 196 (36.0) 45
Data are presented as n or n (%). ATS: American Thoracic Society; ERS: European Respiratory Society; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity.
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A novel approach taken in this study is the assessment of
changes in FVC as a marker of residual volume changes after
bronchodilator administration in patients with severe emphy-
sema. Theoretically, post-bronchodilator improvements in
FVC could be attributed to true bronchodilator effect or
‘‘training’’ effect with patients learning to blow longer with
each subsequent manoeuvre [25]. While we demonstrated that
post-bronchodilator expiratory time was ,1 s longer than pre-
bronchodilator expiratory time, the difference in expiratory
time accounts for only 9% of the variation in post-broncho-
dilator FVC change in these subjects.
Significant improvements in FVC after bronchodilator adminis-
tration in subjects with emphysema were also reported by
O’DONNELL et al. [10] who examined 84 patients with clinically
diagnosed emphysema, ,40% of whom had a o10% improve-
ment in FVC after the administration of 200 mg salbutamol. In our
larger, longitudinal study focusing on a 12% and 400 mL
increase in FVC, a majority of patients (64%) met this criterion
at some point during testing with 45 out of 547 (8.3%) patients
exhibiting such a change at every test. The clinical relevance of
these data should not be underestimated. The change in lung
volume after a bronchodilator has become an important
characteristic in recent studies [10, 26, 27]. This finding is
clinically relevant because such a decrement in lung volume
correlates best with improved breathlessness during exercise
[28] and improvement in symptoms after therapeutic interven-
tions [29, 30]. While relatively fewer patients in our study
demonstrated bronchoreversibility by FEV1 criteria than FVC
criteria, it is possible that in this patient population improve-
ments in FVC may be just as clinically meaningful if not more
meaningful. Interestingly, data from UPLIFT (Understanding
Potential Long-term Impacts on Function with Tiotropium) [7]
demonstrated that the percentage of patients with an isolated
FVC improvement as compared to FEV1 improvement increased
with the severity of airflow obstruction. Thus, pharmacological
lung reduction through bronchodilator therapy is both an
important and obtainable goal in this patient population.
TABLE 4 Comparison of baseline characteristics between those who met and never met the criteria defined by American
Thoracic Society (ATS)/European Respiratory Society (ERS)
Characteristics before rehabilitation ATS/ERS criteria satisfied at least once ATS/ERS criteria never satisfied p-value#
Females/males n 21/100 178/245 ,0.0001
Age yrs 66.78¡6.16 66.35¡5.89 0.485
Pre-BD FEV1 % pred 25.45¡6.32 23.58¡6.70 0.006
Pre-BD FVC % pred 60.57¡15.11 57.41¡15.18 0.044
Post-BD TLC % pred 125.78¡12.32 129.91¡14.13 0.004
DL,CO % pred 31.93¡9.92 27.67¡9.64 ,0.0001
Change in FEV1 L 0.18¡0.09 0.07¡0.07 ,0.0001
Change in FEV1 % 0.24¡0.14 0.12¡0.11 ,0.0001
Smoking history pack-yrs 67.93¡30.93 65.61¡32.06 0.480
Data are presented as mean¡SD, unless otherwise stated. BD: bronchodilator; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity;
TLC: total lung capacity; DL,CO: diffusing capacity of the lung for carbon monoxide. #: calculated using an unpaired t-test, except categorical variables, which used a Chi-
squared test if cell counts were greater than five and a Fisher’s exact test otherwise. More detailed comparisons available in online depository table E4.
TABLE 5 Comparison of baseline characteristics between those who met and never met the criteria defined by forced expiratory
volume in 1 s (FEV1) o400 mL and forced vital capacity (FVC) .400 mL change
Characteristic before rehabilitation FVC o400 mL and 12% satisfied FVC o400 mL and 12% never satisfied p-value#
Females/males n 82/266 117/79 ,0.0001
Age yrs 66.15¡6.20 66.97¡5.46 0.109
Pre-BD FEV1 % pred 23.29¡6.28 25.24¡7.13 0.001
Pre-BD FVC % pred 57.05¡14.80 60.01¡15.78 0.029
Post-BD TLC % pred 128.56¡13.66 129.77¡14.15 0.327
DL,CO % pred 29.44¡10.16 27.16¡9.11 0.010
Change in FEV1 L 0.12¡0.08 0.05¡0.07 ,0.0001
Change in FEV1 % 0.18¡0.13 0.09¡0.11 ,0.0001
Smoking history pack-yrs 69.41¡33.22 60.20¡28.18 0.0012
Data are presented as mean¡SD, unless otherwise stated. BD: bronchodilator; % pred: % predicted; TLC: total lung capacity; DL,CO: diffusing capacity of the lung for
carbon monoxide. #: calculated using an unpaired t-test, except categorical variables, which used a Chi-squared test if cell counts were greater than five and a Fisher’s
exact test otherwise. More detailed comparisons available in online depository table E5.
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A further interesting finding of our study was the relationship
between sex and the likelihood of bronchoreversibility. The
multivariate models in table 6 demonstrate male sex to be
significantly associated with an increased likelihood of
bronchoreversibility by both the ATS/ERS (OR 2.37, 95% CI
1.37–4.12; p50.002) and the increase in FVC by 12% and
400 mL (OR 5.83, 95% CI 3.75–9.07; p,0.0001) criteria, after
adjusting for the percentage of emphysema, age and FEV1. We
know that the smaller airway calibre of females could make
female participants more likely to demonstrate bronchorevers-
ibility due to the fact that airflow resistance is inversely related
to the fourth power of the radius. Thus, for the same degree of
airway dilation, the less the initial airway radius, the greater
the drop in resistance. By adjusting for FEV1, we should
eliminate this sex effect [31]. Limited data are available with
respect to the relationship between sex and bronchodilation in
COPD. An unadjusted sex analysis of the TRISTAN (double
blind, randomised study of salmeterol/fluticasone versus
placebo) data revealed a nonsignificant trend toward a greater
increase in per cent predicted FEV1 with bronchodilator for
males as compared to females, 4.89 versus 4.42 respectively
(p50.18) [32]. TASHKIN et al. [7] examined bronchodilator
responsiveness in patients enrolled in UPLIFT (average FEV1
39.3%) [7]. In that study, males were also more likely to meet
the o12% and o200 mL FEV1 increase threshold in multi-
variate logistic regression. However, females were more likely
than males to demonstrate bronchodilator reversibility using
the criteria of o15% improvement in FEV1 or a o10% absolute
increase in per cent predicted FEV1. If the differences we report
are real, such sex differences would not be surprising. We have
previously reported on other phenotypic differences between
males and females in the NETT patient population, including:
1) overall less severe emphysema in females with the
difference from males most evident in the outer peel of the
lung; and 2) thicker small airway walls relative to luminal
perimeters in females [33].
Finally, we demonstrated that patients with greater fractional
volume of emphysema, as quantified by helical CT, have a
decreased likelihood of demonstrating bronchoreversibility
defined by a spirometric volume criterion. This finding
persisted even when the data were adjusted for severity of
airflow obstruction by the FEV1. Similarly, after adjusting for
baseline pulmonary function, the odds of meeting ATS/ERS
criteria for bronchoreversibility decreased as the quantity of
emphysema increased. Our data agree with and extend a
previous analysis of bronchoreversibility in COPD patients in
which the extent of emphysema was measured by decreased
DL,CO [10] but are in contrast to the finding of similar overall
bronchoreversibility independent of emphysema extent in a
smaller cohort of COPD patients [34]. In our cohort, both DL,CO
and per cent emphysema were significant predictors of
bronchoreversibility in a univariate model. Importantly, how-
ever, in a multivariate model that included both variables, only
the quantity of emphysema remained a significant predictor of
bronchoreversibility. Thus, the quantity of emphysema is
better than DL,CO for predicting the absence of bronchorevers-
ibility. It might be argued that this increased diagnostic
efficiency does not justify the expense and radiation exposure
of HRCT.
The percentage rise in FEV1 after bronchodilator administra-
tion has precedent as an important phenotypic marker in
COPD. Although some investigators have suggested that the
percentage rise in FEV1 positively correlates with survival, this
relationship has not been noted when the post-bronchodilator
FEV1 was substituted for the pre-bronchodilator FEV1 [35].
This has been confirmed by others who noted that the degree
of reversibility did not improve the ability to predict survival
when the best FEV1 per cent predicted was included in the
model [36]. Similarly, the ISOLDE and Lung Health Study data
suggest that bronchoreversibility is not associated with
subsequent decline in pulmonary function [37] or the number
of exacerbations [5]. In contrast, in patients with a1-antitrypsin
deficiency, bronchoreversibility was associated with a greater
rate of decline in FEV1 [38]. Several other studies have also
reported bronchoreversibility to be associated with a greater
rate of decline in FEV1 in subjects with moderately to severely
advanced COPD [39, 40]. Our data expand these results by
confirming a significant decrease in bronchoreversibility in
patients with increasing emphysema quantified by helical CT.
As such, these data support differing clinical phenotypes of
obstructive lung disease as determined by quantitative
measurement of emphysema using CT. It should also be noted
that minimal spirometric change does not necessarily mean
lack of functional improvement or lung volume change after
bronchodilator, even in this severely emphysematous group of
patients. Post-bronchodilator spirometric testing may not
necessarily be best way to assess benefit from bronchodilator
in patients with such severe disease.
Our study has several limitations. First, all subjects were
referred for the evaluation of surgical therapy for COPD,
making a bias towards more severe airflow obstruction and
increasing emphysema likely. The likelihood of such a bias is
supported by the low mean FEV1 and the high percentage of
emphysema noted in our cohort. Secondly, we examined
bronchodilator response to two inhalations of albuterol by
metered-dose inhaler after 15 min. Although recent data
TABLE 6 Multivariate logistic models where the outcome
has a value of 1 if the patient ever met the
bronchoreversibility criterion#
Predictor OR (95% CI) p-value
12% change in FVC as well as a 400 mL
increase
10% increase in whole lung emphysema
(-950 HU)
0.80 (0.67–0.96) 0.01
Male sex 5.83 (3.75–9.07) ,0.0001
Age (10-yr increase) 0.60 (0.43–0.84) 0.003
0.1-L increase in absolute FEV1 0.99 (0.90–1.09) 0.87
ATS/ERS criteria
10% increase in whole lung emphysema
(-950 HU)
0.88 (0.72–1.08) 0.23
Male sex 2.37 (1.37–4.12) 0.002
Age (10-yr increase) 0.96 (0.67–1.37) 0.81
0.1-L increase in absolute FEV1 1.25 (1.13–1.38) ,0.0001
FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; ATS:
American Thoracic Society; ERS: European Respiratory Society. #: n5544.
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suggest that higher doses of inhaled bronchodilators may
result in increased bronchodilation [41], the dose of albuterol
chosen in our study simulates standard clinical practice [21,
42]. The latter two considerations imply that our data may be a
minimal estimate of the degree of bronchoreversibility in this
patient population. In light of the recently adopted ATS/ERS
guidelines which allow for four inhalations of albuterol for
bronchodilator testing [43], future studies may show greater
prevalence of bronchoreversibility. Finally, some patients with
COPD who do not respond to a b-agonist respond to an anti-
cholinergic bronchodilator, which would also suggest our data
may underestimate the true prevalence of bronchodilator
responsiveness in this patient population. Additional studies
evaluating patients with a broader range of obstruction and
quantity of emphysema are needed to confirm our findings.
In summary, we confirm that spirometric bronchodilator
response is seen in some patients with severe airflow
obstruction and increased emphysema volume determined
by CT. Furthermore, we document a significantly decreased
likelihood of meeting ATS/ERS bronchoreversibility criteria
for patients with increased emphysema volume determined by
helical CT. Importantly, a majority of emphysema patients
exhibit lung volume reversibility after the administration of a
short-acting bronchodilator. These subjects tend to have more
severe disease physiologically and anatomically and are more
likely to be males. These data provide additional data
regarding the physiological and radiological phenotype of
patients with severe COPD.
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